التفاصيل البيبلوغرافية
| العنوان: |
Rituximab vs Ocrelizumab in Relapsing-Remitting Multiple Sclerosis. |
| المؤلفون: |
Roos, Izanne, Hughes, Stella, McDonnell, Gavin, Malpas, Charles B, Sharmin, Sifat, Boz, Cavit, Alroughani, Raed, Ozakbas, Serkan, Buzzard, Katherine, Skibina, Olga, van der Walt, Anneke, Butzkueven, Helmut, Lechner-Scott, Jeannette, Kuhle, Jens, Terzi, Murat, Laureys, Guy, Van Hijfte, Liesbeth, John, Nevin, Grammond, Pierre, Grand'Maison, Francois, Soysal, Aysun, Jensen, Ana Voldsgaard, Rasmussen, Peter Vestergaard, Svendsen, Kristina Bacher, Barzinji, Ismael, Nielsen, Helle Hvilsted, Sejbæk, Tobias, Prakash, Sivagini, Stilund, Morten Leif Munding, Weglewski, Arkadiusz, Issa, Nadia Mubder, Kant, Matthias, Sellebjerg, Finn, Gray, Orla, Magyari, Melinda, Kalincik, Tomas |
| المصدر: |
JAMA Neurol ; ISSN:2168-6157 ; Volume:80 ; Issue:8 |
| بيانات النشر: |
Silverchair Information Systems |
| سنة النشر: |
2023 |
| المجموعة: |
PubMed Central (PMC) |
| الوصف: |
Ocrelizumab, a humanized monoclonal antibody targeted against CD20+ B cells, reduces the frequency of relapses by 46% and disability worsening by 40% compared with interferon beta 1a in relapsing-remitting multiple sclerosis (MS). Rituximab, a chimeric monoclonal anti-CD20 agent, is often prescribed as an off-label alternative to ocrelizumab. |
| نوع الوثيقة: |
article in journal/newspaper |
| اللغة: |
English |
| العلاقة: |
https://doi.org/10.1001/jamaneurol.2023.1625Test; https://pubmed.ncbi.nlm.nih.gov/37307006Test; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10262062Test/ |
| DOI: |
10.1001/jamaneurol.2023.1625 |
| الإتاحة: |
https://doi.org/10.1001/jamaneurol.2023.1625Test
https://pubmed.ncbi.nlm.nih.gov/37307006Test
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10262062Test/ |
| رقم الانضمام: |
edsbas.F819BB4B |
| قاعدة البيانات: |
BASE |
